Cellular Biomedicine Group, Inc. , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce positive results from its Phase I clinical trial, which evaluated the safety of TC-DC therapy for hepatocellular carcinoma , the most common type of liver cancer.
http://ift.tt/1fb9wpa
http://ift.tt/1fb9wpa
No comments:
Post a Comment